Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients with Different Types of Influenza: A Multiseason Cohort Study

Clinical Infectious Diseases

Volumn 69, Issue 11, 2019, Pages 1896-1902

  Lytras, Theodore ^a   Mouratidou, Elisavet ^a,b   Andreopoulou, Anastasia ^a   Bonovas, Stefanos ^c,d   Tsiodras, Sotirios ^a,e  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c HUMANITAS UNIVERSITY   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

influenza; intensive care units; mortality; oseltamivir; survival analysis

Indexed keywords

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; GREECE; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEASONAL INFLUENZA; THERAPY DELAY; CRITICAL ILLNESS; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OSELTAMIVIR; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85067123080     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciz101     Document Type: Article

References (32)

1. Iuliano AD, Roguski KM, Chang HH, et al; Global Seasonal Influenza-Associated Mortality Collaborator Network. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391:1285-300.
2. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
3. Harper SA, Bradley JS, Englund JA, et al; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
4. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. BMJ 2014; 348:g2263.
5. Louie JK, Lampiris H. Treating influenza with neuraminidase inhibitors: what is the evidence? JAMA Intern Med 2015; 175:1899-900.
6. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4:CD008965.
7. Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess 2016; 20:1-242.
8. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
9. Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ 2014; 348:g2371.
10. Jones M, Del Mar C, Hama R. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med 2014; 2:e9-10.
11. Wolkewitz M, Schumacher M. Survival biases lead to flawed conclusions in observational treatment studies of influenza patients. J Clin Epidemiol 2017; 84:121-9.
12. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 2013; 100:520-34.
13. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-44.
14. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339-45.
15. Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M. Interpreting and comparing risks in the presence of competing events. BMJ 2014; 349:g5060.
16. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. Semiparametric survival models. In: The BUGS book: a practical introduction to Bayesian analysis. Boca Raton, FL: CRC Press, 2012:288-91.
17. Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Vienna: Proceedings of the 3rd international workshop on distributed statistical computing, 2003:135. Available at: https://www. r-project. org/ conferences/DSC-2003/Proceedings/Plummer. pdf
18. Neuraminidase inhibitors for influenza: a call for better research. Lancet 2015; 386:1510.
19. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
20. Garten R, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2017-18 season and composition of the 2018-19 influenza vaccine. MMWR Morb Mortal Wkly Rep 2018; 67:634-42.
21. Beyersmann J, Gastmeier P, Schumacher M. Incidence in ICU populations: how to measure and report it? Intensive Care Med 2014; 40:871-6.
22. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
23. Baum SG. Oseltamivir and the influenza alphabet. Clin Infect Dis 2006; 43:445-6.
24. Antes G, Meerpohl JJ. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med 2014; 2:e10.
25. Duggal A, Pinto R, Rubenfeld G, Fowler RA. Global variability in reported mortality for critical illness during the 2009-10 influenza A(H1N1) pandemic: a systematic review and meta-regression to guide reporting of outcomes during disease outbreaks. PLoS One 2016; 11:e0155044.
26. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
27. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553-63.
28. Rello J, Pop-Vicas A. Clinical review: primary influenza viral pneumonia. Crit Care 2009; 13:235.
29. Jain A, van Hoek AJ, Boccia D, Thomas SL. Lower vaccine uptake amongst older individuals living alone: a systematic review and meta-analysis of social determinants of vaccine uptake. Vaccine 2017; 35:2315-28.
30. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 2013; 66:648-53.
31. Dunn AG, Arachi D, Hudgins J, Tsafnat G, Coiera E, Bourgeois FT. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med 2014; 161:513-8.
32. Academy of Medical Sciences, Wellcome Trust. Use of neuraminidase inhibitors in influenza. 2015. Available at: https://acmedsci. ac. uk/policy/policy-projects/ treating-influenza. Accessed 22 July 2018.